Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emicizumab for hemophilia A with factor VIII inhibitors.
Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Young G, et al. Expert Rev Hematol. 2018 Nov;11(11):835-846. doi: 10.1080/17474086.2018.1531701. Epub 2018 Oct 10. Expert Rev Hematol. 2018. PMID: 30278802 Review.
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, Symington E, Quon DV, Wang JD, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O'Mahony B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, Yang X, Wong WY, Kim B; GENEr8-1 Trial Group. Ozelo MC, et al. N Engl J Med. 2022 Mar 17;386(11):1013-1025. doi: 10.1056/NEJMoa2113708. N Engl J Med. 2022. PMID: 35294811 Clinical Trial.
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, Mahlangu J, Young G, Kruse-Jarres R, Mancuso ME, Niggli M, Howard M, Bienz NS, Shima M, Jiménez-Yuste V, Schmitt C, Asikanius E, Levy GG, Pipe SW, Oldenburg J. Callaghan MU, et al. Blood. 2021 Apr 22;137(16):2231-2242. doi: 10.1182/blood.2020009217. Blood. 2021. PMID: 33512413 Free PMC article. Clinical Trial.
Managing Severe Hemophilia A in Children: Pharmacotherapeutic Options.
Regling K, Callaghan MU, Sidonio R Jr. Regling K, et al. Among authors: callaghan mu. Pediatric Health Med Ther. 2022 Feb 15;13:27-35. doi: 10.2147/PHMT.S293246. eCollection 2022. Pediatric Health Med Ther. 2022. PMID: 35210899 Free PMC article. Review.
Early stage clinical trials for the treatment of hemophilia A.
Guzzardo GM, Sidonio R Jr, Callaghan MU, Regling K. Guzzardo GM, et al. Among authors: callaghan mu. Expert Opin Investig Drugs. 2022 Nov;31(11):1169-1186. doi: 10.1080/13543784.2022.2138742. Epub 2022 Nov 9. Expert Opin Investig Drugs. 2022. PMID: 36265129 Review.
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
Skinner MW, Négrier C, Paz-Priel I, Chebon S, Jiménez-Yuste V, Callaghan MU, Lehle M, Niggli M, Mahlangu J, Shapiro A, Shima M, Campinha-Bacote A, Levy GG, Oldenburg J, von Mackensen S, Pipe SW. Skinner MW, et al. Among authors: callaghan mu. Haemophilia. 2021 Sep;27(5):854-865. doi: 10.1111/hae.14363. Epub 2021 Jun 25. Haemophilia. 2021. PMID: 34171159 Free PMC article.
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.
Escobar M, Castaman G, Boix SB, Callaghan M, de Moerloose P, Ducore J, Hermans C, Journeycake J, Leissinger C, Luck J, Mahlangu J, Miesbach W, Mitha IH, Négrier C, Quon D, Recht M, Schved JF, Shapiro AD, Sidonio R Jr, Srivastava A, Stasyshyn O, Vilchevska KV, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Macie C, Wilkinson TA, Kessler C. Escobar M, et al. Haemophilia. 2021 Nov;27(6):921-931. doi: 10.1111/hae.14419. Epub 2021 Oct 11. Haemophilia. 2021. PMID: 34636112 Free PMC article. Clinical Trial.
76 results